U.S. market Closed. Opens in 16 hours 8 minutes

PMCB | PharmaCyte Biotech, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for PMCB we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is very wealthy, Growth is desperately bad and Health is frighteningly weak.

Valuation (45%)

Company Industry
P/E Ratio (TTM) 0.52 -22.37
PEG Ratio (TTM) 0.00 15.65
P/S Ratio (TTM) N/A 49.21
P/B Ratio (TTM) 0.27 18.45
P/FCF Ratio (TTM) -4.79 -1.64
Price to 5YR AVG Earnings Ratio -1.00 -2.80
Price to 5YR AVG FCF Ratio -4.37 -8.54

Profitability (75%)

Company Industry
ROA (TTM) 38.38% -4.65%
ROE (TTM) 54.01% 20.33%
Net Profit Margin (TTM) N/A -1,544.80%
ROIC 5YR AVG 587.39% 16.10%

Growth (27%)

4QTR AVG 3YR AVG 5YR AVG
EPS 364.82% 51.69% -109.55%
Revenue N/A N/A N/A
Net Income 505.49% -0.64% -61.39%
Cash Flow -171.91% -15.77% 0.77%

Health (26%)

Company Industry
Current Ratio (TTM) 4.40 6.09
Quick Ratio (TTM) 4.40 5.81
D/E Ratio (TTM) N/A -16.41
Interest Coverage (TTM) N/A -0.80
Piotroski F-Score 2 5
Altman Z-Score 0.25 13.80
LTL to 5YR AVG FCF N/A 0.17
Shares Outstanding Growth 5YR AVG 206.08% 128.83%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙